Index

abstract thinking. *See* cognition, abstract thinking.
abulia, 6
abuse, 226, 227
acetylcholinesterase inhibitors, 10
  donepezil, 33–36, 43–44, 96, 112, 132–33, 179–81, 187
  galantamine, 10, 220
  rivastigmine, 10, 39–40, 42, 65, 125, 155, 164, 173
activities of daily living (ADL), 24–26, 173, 175, 178, 184–85, 186, 215–18
  bathing, 32–34, 52–53, 59, 79, 81, 83, 133, 135
  dressing, 24, 28, 30, 66, 71, 179, 183, 196
  mobility, 7, 66, 68, 123, 179–81, 183, 185, 202, 203
  toileting, 7, 9, 13, 120, 123, 126, 198, 202 *See also* incontinence.
  transferring, 66, 179, 202, 203
  wayfinding, 91, 114, 115, 143–44, 159, 183 *See also* instrumental activities of daily living.
adjustment disorder, 36, 46, 48, 73, 166, 239
advance care planning. *See* care planning.
aggression, 29, 203–4, 213, 238
agitation, 10, 29, 229, 238
alcohol use, 7, 188, 189, 212, 242
alexia, 6
allopurinol, 51, 57, 124
Alzheimer's disease
  aetiology, 6
  age of onset, 113
  comorbidities. *See* comorbidities.
  diagnosis, 8, 15, 32
    cognitive tests, 46, 48, 55 *See also* cognitive function.
    differential diagnosis, 50, 112, 153, 182, 197, 213
    early detection, 13
    imaging, 100
    symptom presentation, 25, 34, 43, 59, 106, 118–19
  neuropathology, 6, 55
    amyloid plaques, 6, 32, 54, 55, 69, 71, 112, 114
    frontal lobe, 67, 110, 164, 171, 191
    hippocampal sclerosis, 32, 94, 110
  prevalence, 5
  progression, 8, 9, 12–13, 63, 115
    severe stage, 34, 36
  risk factors, 98, 115
    cardiovascular, 23, 114
    cerebral, 42
Alzheimer's Disease International (ADI), 1, 10, 220, 237
ambulation. *See* mobility.
amlodipine besylate, 57, 102, 108, 162, 164, 169, 173, 174
amyloid cascade hypothesis, 6
amyloid plaques, 6, 137, 144, 153, 170, 177
  cerebral load, 48, 63, 69, 71, 73, 131, 137, 144
  cognitive reserve against, 54, 55, 69
  deposition, 170
  hippocampal sclerosis and, 32, 94
  imaging for, 114
anaemia, 84
antidepressants, 77, 164, 187, 194
antipsychotics, 30, 32, 34, 61, 63, 205, 237, 238
anxiety, 40, 42, 46, 90, 135, 136, 166, 187
apraxia, 81, 83, 127, 191, 209–14, 226, 234
aspirin, 98, 110, 138, 164, 169, 173, 194
asthma, 79–80, 106
atrial fibrillation, 45–46, 56, 94, 96–126, 130, 132, 162
attention deficit, 6, 24, 36, 75, 96–97, 113–14, 186, 201–2

Barthel Index, 24, 25–26, 36–38, 43, 50–53, 68–70, 73–75, 81–83
basal ganglia, 6, 110, 173
bathing, 32–34, 52–53, 59, 79, 81, 83, 133, 135
bed/chair transfers, 66, 179, 202, 203
behavioural dysfunction, 66–67, 135, 189, 191, 196–98, 230, 231, 238–39
  aggression, 29, 203–4, 213, 238
  agitation, 10, 29, 229, 238
  disinhibition, 6, 214, 238
  hoarding, 7, 197, 239
behavioural dysfunction, overeating, 29, 66–67, 120, 178–79, 213, 214
biopsychosocial model, 11, 149, 218, 239
bladder incontinence. *See* urinary incontinence.
blood assays
  complete blood picture, 45, 47, 92, 96, 108, 171, 173
  ESR (erythrocyte sedimentation rate), 41, 60, 92, 96, 110, 138, 149, 216
  TSH (thyroid-stimulating hormone), 45, 96, 149, 150, 152, 154, 156, 173
blood pressure, 72, 136, 138, 166
bowel control, 73, 159, 179, 196, 202

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 16 Nov 2026 at 17:50:52, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781108989336.009

bradycardia, 94, 195–96
bradykinesia, 6, 50, 199, 213
brain imaging. *See* imaging.
brain insulin resistance, 115
brain reserve, 170 See cognitive reserve.
bronchiectasis, 31

Calcichew, 49, 108, 138
cancer, 104, 162, 174
care homes, 123, 226
care planning, 10–14, 55, 57, 83, 106, 119, 225–28
  Certified Dementia Care Planner, 10, 14
  integrated care, 10, 13
carers, 4, 23, 30, 108, 111, 112, 176, 229–31, 234–36, 246–47
  assessment by, 71, 75, 123, 129
  community care and, 4
  delusions involving, 34, 110
  domestic assistance, 34, 77, 170, 172–73, 180, 188, 194, 207–8
  family members as, 50–52, 54, 77, 226, 230, 231–33, 238–41
  preparation for deterioration, 44, 191
  primary care and, 15, 23, 24, 86
  prompting by, 34, 88
  reports by, 23, 27, 71, 191, 236
  skills and education, 30, 50, 52, 82–83, 86, 104, 111, 203
    communication skills, 34, 36, 44, 117, 137, 172, 233
    preparation for deterioration, 44, 191
  specialist care and, 4, 13
  well-being and support of, 2, 10–12, 199, 209
  stress, 102, 170, 189, 204, 210–12, 225, 229–30, 231
care services and resources, 237, 240
  community centres, 4, 38, 100, 132, 142, 162
  day care, 11, 52, 133, 168, 198, 199
  social support networks, 57, 59, 73, 166, 215, 229
  social workers, 4–5, 13, 46, 79, 81, 117–19, 131, 186–88
  technology
    location-tracking devices, 26, 30, 38, 48, 65, 79, 97, 100
carotid bruit, 84, 130, 132, 162, 171, 197
cataract, 25, 66, 68, 109, 110, 145, 149, 156
CBD. *See* cortobasical degeneration.
CBP. *See* complete blood picture.
CDR. *See* Clinical Dementia Rating.
cerebral atrophy, 52, 82, 88, 106, 108, 110, 124, 127
cerebral infarction, 187
cerebrovascular accident, 40–42, 126, 169–70, 173, 179–80, 182, 202
cervical myelopathy, 124
chlordiazepoxide, 169
cholinesterase inhibitors, 23, 63, 77, 92–93, 94, 127, 156, 184
chronic illnesses, 64, 80, 236
circadian cycle. 26, 48 *See also* sleep.
Clinical Dementia Rating (CDR), 8, 47–72, 75–76, 96–97, 139–41, 217, 219
  mild dementia, 49, 118
  moderate dementia, 53, 58, 60, 62, 118, 150, 188, 200
  questionable dementia, 45
Clock Drawing Test, 24
  clock copying section, 61, 63, 65, 70, 71–73, 161, 163, 165
  not completed, 24, 65, 77, 79, 80, 148, 150
  executive element impairment, 24, 25–26, 30–31, 34, 36, 61, 63, 65
  no impairment, 24, 29, 47, 48, 139, 163, 172, 180
  interlocking pentagon task and, 92, 100
  sensitivity, 38
  significant impairment, 28, 32, 42, 56, 58, 61, 81, 93
  slight impairment, 24, 28, 50, 84, 123, 137, 139
  time denotation, 36, 38, 40, 91, 93, 139–63, 165
clopidogrel, 134
clothing, 28, 30, 49, 51, 63–64, 66, 120–21, 126 *See also* dressing.
cognitive function
  abstract thinking, 9, 63, 71, 145, 146, 183, 186, 191
  ADL function and dissociation, 59
  attention deficit, 6, 24, 36, 75, 96–97, 113–14, 186, 201–2
  cognitive frailty, 75, 112, 146, 153, 175, 192, 194–95, 201
  deterioration, 34, 36, 55, 73, 78, 92, 201, 206
  executive function, 6, 7, 22–24, 63–64, 108–9, 145–46, 166–68, 170
  naming, 22, 145, 146, 183, 186, 191
  screening tests, 7, 36, 46, 52, 55, 209, 212, 216–18
cognitive reserve, 54, 55, 114, 115, 119, 131, 210, 215
cognitive stimulation therapy (CST), 10, 160, 233, 237–38
cognitive tests. *See* cognitive function, screening tests.
colchicine, 57
community care, 75–77, 79, 81, 99, 101–2, 133, 240–42, 247
community centres, 4, 38, 100, 132, 142, 162
community engagement (of patient), 9, 49–50, 76, 101, 122, 141, 167, 168
comorbidities, 6, 12, 53–54, 178, 239
  anaemia, 83, 84
  cardiovascular conditions, 39
  chronic illnesses, 80, 236
  depression, 4, 46, 61, 89
  urinary tract infection, 96

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 16 Nov 2026 at 17:50:52, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781108989336.009

comorbidities (cont.)
vascular dementia, 46, 57
See also mixed dementia.
complete blood picture, 45, 47, 92, 96, 108, 171, 173
computed tomography. *See* CT.
conduction dysphasia, 182
Cornell Scale for Depression in Dementia, 55
corticobasal degeneration, 126–27, 213–14
counselling, 14, 36, 46, 227, 232
CT (computed tomography imaging), 41–42, 59, 60, 88, 177, 182, 190–91, 215–16

daily living activities. *See* activities of daily living.
day care, 48, 50, 52, 71, 72–73, 74, 132–33, 167–68
deafness. *See* hearing impairment.
delayed recall, 34, 38, 42–44, 105–7, 135, 139–41, 149–50, 174–75
delirium, 147, 171, 192, 209, 213, 239
delusions, 31–35, 60–63, 89–91, 107–14, 116–18, 153–54, 169–72
defined, 212
depression, 45–47, 58–170, 184–88
assessments in case studies, 45, 46, 57, 76, 89–91
carer stress and, 142
IADL dependency and, 42
pharmacological interventions, 77, 102, 164, 187, 194
prevalence, 219
as pseudodementia, 7
as risk factor, 92
suicidal ideation and, 101
Describe, Investigate, Create, Evaluate (DICE) model, 238
diabetes, 90–92, 98, 115, 173, 174, 177, 178, 239
dialectic model, 11
diazoxide, 174
diet, 34, 35, 59, 61, 84, 86, 113, 177–79
digoxin, 57, 94, 96
disinhibition, 6, 214, 238
disorientation, 24, 32, 35, 57, 61, 95, 199–200, 202
distressed behaviours, 40, 196, 201, 204, 229, 230, 238
DLB. *See* Lewy body dementia.
donepezil, 33–36, 43–44, 96, 112, 132–33, 179–81, 187
dressing, 24, 28, 30, 66, 71, 179, 183, 196
drinking. 7 *See* alcohol use.
dyslipidaemia, 98, 106, 124, 126, 162, 164, 169, 173

early dementia, 15, 50, 70, 81, 87, 108, 177, 213–14
early detection services, 13, 209, 215, 216, 218, 231, 234, 241
EDS (Hong Kong), 13–15
early intervention services, 1, 4–13, 83, 84, 209, 215, 220
end-of-life care, 209, 228
enduring power of attorney (EPA/EPOA), 13, 191, 227
escitalopram, 135, 187, 194
esomeprazole, 115
ESR (erythrocyte sedimentation rate), 41, 60, 92, 96, 110, 138, 149, 216
executive function, 6, 7, 22–24, 63–64, 108–9, 145–46, 166–68, 170
exercise (physical), 10, 27–28, 31–32, 34, 59, 86, 231, 238

family care. *See* carers.
famotidine, 45, 88, 171
fasting lipids profile, 45, 47–98, 124, 127, 171, 173
fasting sugar profile, 94, 96–173, 202–3
FAST. *See* Functional Assessment Staging.
flupentixol, 169
forgetfulness. *See* memory impairment.
frailty, 75, 110, 125, 127, 153, 157, 194, 234–36
frontal lobe pathology, 67, 110, 164, 171, 191
frontotemporal dementia (FTD), 6–7, 8, 15, 179, 190–91, 204, 208, 213–14
Functional Assessment Staging (FAST), 8, 12, 129, 151, 209, 219, 226

gait abnormalities. 6, 123, 130, 132, 162, 171 *See also* ambulation; mobility.
galantamine, 10, 220
gaze palsy, 50
GDS. *See* Global Deterioration Scale.
General Practitioner Assessment of Cognition. *See* GPCOG.
glaucoma, 145, 149
Global Action Plan on the Public Health Response to Dementia 2017–2025, 2, 220
Global Deterioration Scale, 8, 217, 219
goitre, 45
gout, 23, 29, 31, 56, 74, 78, 86, 124
GPCOG Informant Interview, 211–12
grocery shopping. *See* shopping.

hallucinations, 6, 10, 123, 125, 172, 189, 199–201, 213 *See also* delusions.
head injury, 98–99, 212, 216
hearing impairment, 47, 138–39, 150–51, 204, 215, 242
heart disease, 60, 98, 124, 138, 156, 169
hippocampal sclerosis, 32, 94, 110
hip replacement, 25, 33, 45, 202, 239
hoarding, 7, 197, 239
hobbies, 74, 97, 99, 103, 105, 122, 143–44
home care, 3, 11–13
home modifications, 12, 100, 166

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 16 Nov 2026 at 17:50:52, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781108989336.009

home safety, 4, 129, 166, 225
household tasks, 26, 95, 107, 129, 136, 198, 201
housekeeping, 24–26, 51, 53, 58, 60, 73, 117
hygiene
  environmental, 65, 68, 126, 139
  personal, 6, 120, 126–31, 139, 196–97, 214, 239
hypercholesterolaemia, 115, 116, 177, 178, 180, 182, 202, 204
hyperlipidaemia, 56, 90, 188
hyperorality, 7
hyperplasia, 31, 80, 118, 124, 174, 196–97, 199, 204
hypertension, 29, 31, 66, 72–150
hypotension, 6, 195–96
hysterectomy, 88, 173

ICD-11, 8
imaging, 3, 8, 46, 100, 191, 196, 208, 216
  CT (computed tomography), 41–42, 59, 60, 88, 177, 182, 190–91, 215–16
  See also magnetic resonance imaging(MRI)
    X-ray, 3
incontinence, 198, 214
  bowel control, 73, 159, 179, 196, 202
  urinary, 6, 47, 73, 89, 96–97, 126, 196, 202
independence, 69, 78–79, 83–85, 110, 129, 142, 144, 146
insomnia. *See* sleep.
Instrumental Activities of Daily Living (IADL), 218
  aids and support
    reminders, 26, 85, 127–29, 137, 153–55, 159, 163–64, 197–98
  assessment tools, 218
  grocery shopping, 24–26, 36, 38, 58, 60, 64, 66, 68
  laundry, 24, 26, 51, 53, 58, 60, 73, 75
  meal preparation, 24, 28, 47, 49, 58, 60, 87, 193–95
  medication management, 47, 104, 125, 211, 234
integrated care, 10, 13
ipratropium bromide, 80, 124
irritability. *See also* aggression, 29, 61, 90, 91, 123, 164, 189–91, 207
isosorbide dinitrate, 96
isosorbide mononitrate, 124, 138

language impairment, 34, 38, 54–55, 81–83, 100–1, 121–25, 190–91, 207–8
laundry, 24, 26, 51, 53, 58, 60, 73, 75
Lewy body dementia, 6, 8, 10, 50, 125, 199, 200, 213
life events, 11–12, 233
lifestyle factors, 52, 54, 179, 242
  alcohol use, 7, 188, 189, 212, 242
  smoking, 7, 215, 242
living tasks. *See* activities of daily living (ADL).
location-tracking devices, 26, 30, 38, 48, 65, 79, 97, 100
low motivation, 52, 77, 87, 92, 109, 133, 163, 172

magnetic resonance imagine (MRI), 45–46, 47, 106, 113, 140, 169, 205–6, 215–16
meal preparation, 24, 28, 47, 49, 58, 60, 87, 193–95
mecobalamin, 84, 163
medial lateral temporal atrophy, 57, 82, 140, 171
mediastinum, 138
memantine, 55, 59, 61, 179, 181, 182, 184, 237
memory clinics, 3–5, 13, 92
memory impairment, 47, 48, 71, 72–161
  Alzheimer's disease early stage, 8
  carer concerns, 72–129
  delayed recall, 34, 38, 42–44, 105–7, 135, 139–41, 149–50, 174–75
  deterioration, 79, 117, 125, 129, 166, 168
  family reported, 22–24, 59–81, 89–91
  IADL and, 51
  Lewy body dementia, 6
  masking, 110
  misplacement of belongings, 121, 139, 141, 144
  patient insight, 48
meningioma, 110, 206
mental health, 147, 196, 212, 229, 239–40
  anxiety, 40, 42, 46, 90, 135, 136, 147, 166, 187
  See also depression.
  suicidal ideation, 101, 102, 189, 227
metformin, 92, 98–99, 124, 126, 162–63, 173
methotrexate, 49
methyldopa, 185–86
metoprolol succinate, 169, 173
mild cognitive impairment (MCI), 7–19, 153, 162, 164, 168, 173, 175, 177
mild dementia, 41, 47, 49, 118, 145–46, 159–60, 176–77
Mini-Mental State Examination. *See* MMSE.
mixed dementia, 61, 88, 102, 127, 182, 203, 237
MMSE (Mini-Mental State Examination), 168, 191, 216–17, 234
  interlocking pentagon task, 34, 38, 90, 92, 99, 100, 158, 160
mobility, 66, 68, 123, 179–81, 183, 185, 202, 203
moderate Alzheimer's disease, 9, 29, 70–71, 76, 78, 83, 234, 237
moderate cognitive impairment, 123
moderate dementia, 4, 10, 28, 30, 35, 40, 66
Montreal Cognitive Assessment (MoCA), 145, 146, 147, 155–56, 161–62, 168, 170, 217–18

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 16 Nov 2026 at 17:50:52, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781108989336.009

mood change. 46–47, 56–58, 76–77, 89–90, 92–95, 99–103, 107–10, 185–86 *See also* depression.
morphine, 138
Multispecialty Interprofessional Teams, 4

naming, 22, 145, 146, 183, 186, 191
National Dementia Strategy, 3
neurofibrillary tangles, 6
neuroimaging. *See* imaging.
neuroleptics, 90, 172, 237
Neuropsychiatric Interview Questionnaire, 55
NICE (National Institute for Health and Care Excellence), 5, 215, 220, 237, 240
non-Alzheimer's dementia, 29, 31, 35, 37, 43, 45, 49, 213–14
non-pharmacological interventions, 10–11, 12, 23–24, 30, 32, 40, 112, 237

object agnosia, 6
obstructive pulmonary disease, 80, 96, 124
occupational therapists, 4–5, 10, 13, 144
old age, extreme, 32
osteoarthritis, 23, 88, 173, 195, 204
osteoporosis, 45, 138, 156
overeating, 29, 66, 120, 178–79, 213, 214

palliative care. *See* end-of-life care.
pancytopenia, 31
pantoprazole, 49, 94, 98, 102, 110, 126, 156, 164
paracetamol, 126, 171
Parkinson disease dementia (PDD), 10, 50, 213
parkinsonism, 6, 50, 125, 189, 198–99, 213–14
  atypical, 50
  bradykinesia, 6, 50, 199, 213
pepcidine, 169
personal care. 9, 72, 74, 76, 101, 167 *See also* activities of daily living (ADL).
personality change, 6, 11, 32, 100, 133, 206–8, 229, 231
person-centred care, 2, 5, 11, 15, 40, 226, 238
PET (positron emission tomography), 6, 177
physical exercise, 10, 238
power of attorney (EPA/EPOA), 13, 191, 227
primary care, 1–18, 62–81, 84–110, 147–75
  carers and, 236
  diagnostic accuracy, 15
  key considerations, 232, 237
  models, 3, 11
    with specialist outreach, 3
  prescribing, 10
  resources for, 212
  roles, 11–12, 15
  service integration, 5, 12
  specialist care and, 3
primary progressive aphasia (PPA), 8, 96, 213–14
pseudobulbar palsy, 6
pseudodementia. *See* depression.
psychiatric disorders. 31, 33, 35, 37, 43, 45, 49, 51 *See also* depression; mental health.
psychoeducation, 36, 46, 102, 106, 229–30
psychomotor retardation, 6
psychotherapy, 46, 92, 188
public awareness, 59, 153, 241

Quality and Outcomes Framework, 3
quetiapine, 30, 63, 125, 188–89

radiation therapy, 162
rapid eye movements behaviour disorder (REMBD), 6, 125, 172, 189, 199, 213
reminders, 26, 85, 127–29, 137, 153–55, 159, 163–64, 197–98
residential care. *See* care homes.
resistance to care, 52, 238
Resources for Enhancing Alzheimer's Carer Health, 10
rigidity, 6, 104, 213, 237
risk factors, 114, 242
  cardiovascular, 7, 23, 114, 115, 177, 180, 239, 242
  cerebral, 42, 84
  chronic disease, 92
  diabetes, 42, 115
  See also comorbidities.
rivaroxaban, 57
rivastigmine, 10, 39–40, 42, 65, 125, 155, 164, 173

safety, 10, 30, 38, 121, 129, 209, 210, 215
salbutamol, 80, 124
screening tests. 7 *See* cognitive screening tests.
secondary care, 4, 14–15, 102, 104, 208
selective serotonin reuptake inhibitors (SSRI), 67, 90, 102, 108, 135, 171, 197
self-awareness, 55, 73, 106, 108, 163, 166, 206
self-care, 31, 34, 35, 66–67, 69, 82–83, 126–27, 213
shopping, 24–26, 30, 36, 38, 60, 64, 66, 87
simvastatin, 45, 57, 98, 102, 124, 126, 173, 194
sleep, 6, 93, 94, 134, 137, 189, 198–99, 201
small vessel disease, 47, 84, 85–87, 88, 92, 110, 115, 184
smoking, 7, 215, 242
social centres, 11
social interaction, 35, 59, 61, 84, 113, 144, 182–83, 237–38
social workers, 4–5, 13, 46, 79, 81, 117–19, 131, 186–88
specialist care, 1–5, 11, 13–14, 15, 204, 206, 232, 236–37
SSRIs. *See* selective serotonin reuptake inhibitors.
stress (carers), 86, 102, 117, 189, 204, 208, 212, 229
stroke, 6, 95–97, 127–31, 177, 179, 180–82, 203, 212–13

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 16 Nov 2026 at 17:50:52, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781108989336.009

strontium ranelate, 169
subdural haematoma, 22–23, 98, 169, 216
subjective cognitive impairment, 7, 141, 155
suicidal ideation, 101–2, 189, 227
support services. *See* care and support services and resources.
swallowing problems, 13, 66, 214
Swedish Dementia Registry, 3

task-sharing, 1, 14–15
task-shifting, 1, 2, 14–15, 16
temper. *See* irritability.
temporal lobe degeneration, 57, 82–83, 110, 124
thalassemia, 197
thiamine, 189
three-step command task, 24, 30, 32, 42, 44, 51, 53, 56
thyroid function, 8
thyroid-stimulating hormone, 45, 96, 149, 150, 152, 154, 156, 173
toileting, 7, 9, 13, 120, 123, 126, 198, 202 *See also* incontinence.
transferring, 66, 179, 202, 203
tremor, 50, 124, 213
triage, 13, 81, 153, 156, 212, 218, 219, 234

United Kingdom, 3, 5, 209, 215, 236
urinary incontinence, 47, 73, 96–97, 126, 142, 159, 196, 202
utilisation behaviours, 6

valproate, 171, 197, 205
vascular dementia, 42, 96, 102, 106, 177–79, 181, 182, 184
verbal expression, 24, 26, 153, 155, 183–84, 191, 203, 204 *See also* word finding.
verbal function, naming, 22, 145, 146, 183, 186, 191
vildagliptin, 98, 173
visual hallucinations, 6, 50, 66, 160, 198–201, 213
visual impairment, 32, 154 *See also* cataract; glaucoma.

waiting times, 2, 5, 13–15
warfarin, 45, 96, 126
wayfinding, 91, 114, 115, 143–44, 159, 183
word finding, 23, 90–91, 109–10, 158–60, 180–82, 183, 190–91, 200–2 *See also* verbal expression; naming; GPCOG informant interview.
World Alzheimer's Report, 1, 2, 13

X-ray, 127, 134, 138, 140, 158, 160, 166

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 16 Nov 2026 at 17:50:52, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781108989336.009

Downloaded from https://www.cambridge.org/core. UNIVERSIDAD AUTONOMA METROPOLITANA, on 16 Nov 2026 at 17:50:52, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/9781108989336.009